Investigating the collective advantages of sodium-glucose cotransporter-2 inhibitors and GLP-1 analogs in addressing metabolic health issues linked to obese type 2 diabetes mellitus and related comorbidities.
作者信息
Al-Rashid Sulthan, Prasad Monisha, Balasubramanian Rajkapoor, Maideen Naina Mohamed Pakkir
机构信息
Department of Pharmacology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India.
Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India.
出版信息
Indian J Pharmacol. 2025 Mar 1;57(2):104-105. doi: 10.4103/ijp.ijp_559_24. Epub 2025 Jun 13.
Abstract
摘要
相似文献
1
Investigating the collective advantages of sodium-glucose cotransporter-2 inhibitors and GLP-1 analogs in addressing metabolic health issues linked to obese type 2 diabetes mellitus and related comorbidities.研究钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1类似物在解决与肥胖型2型糖尿病及相关合并症相关的代谢健康问题方面的共同优势。
Indian J Pharmacol. 2025 Mar 1;57(2):104-105. doi: 10.4103/ijp.ijp_559_24. Epub 2025 Jun 13.
2
Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a network meta-analysis of population-based cohort studies.在 2 型糖尿病患者中使用二肽基肽酶-4 抑制剂、胰高血糖素样肽-1 受体激动剂或钠-葡萄糖共转运蛋白-2 抑制剂与骨折风险的关系：基于人群队列研究的网络荟萃分析。
Front Endocrinol (Lausanne). 2024 Oct 11;15:1410883. doi: 10.3389/fendo.2024.1410883. eCollection 2024.
3
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD.胰高血糖素样肽-1受体激动剂与钠/葡萄糖协同转运蛋白2抑制剂在预防2型糖尿病合并慢性肾脏病患者慢性肾衰竭及死亡方面的比较疗效
Am J Kidney Dis. 2025 Apr 29. doi: 10.1053/j.ajkd.2025.03.016.
4
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
5
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂治疗 2 型糖尿病：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.
6
Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis.GLP-1 受体激动剂与 SGLT-2 抑制剂在超重/肥胖伴或不伴糖尿病患者中的疗效和安全性：系统评价和网络荟萃分析。
BMJ Open. 2023 Mar 7;13(3):e061807. doi: 10.1136/bmjopen-2022-061807.
7
Health care resource utilization and costs in Medicare Advantage beneficiaries using glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors.使用胰高血糖素样肽-1受体激动剂与钠-葡萄糖协同转运蛋白-2抑制剂的医疗保险优势受益人的医疗保健资源利用情况和成本
J Manag Care Spec Pharm. 2025 Jul;31(7):627-640. doi: 10.18553/jmcp.2025.31.7.627.
8
Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽 1 激动剂和二肽基肽酶 4 抑制剂与 2 型糖尿病患者肾脏结局的关系：系统评价和网络荟萃分析。
PLoS One. 2022 Apr 14;17(4):e0267025. doi: 10.1371/journal.pone.0267025. eCollection 2022.
9
Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.2型糖尿病患者中钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽受体激动剂治疗心房颤动的比较：随机对照试验网络荟萃分析的系统评价
J Cardiovasc Pharmacol. 2022 Mar 1;79(3):281-288. doi: 10.1097/FJC.0000000000001197.
10
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽 1 受体激动剂和二肽基肽酶 4 抑制剂与 2 型糖尿病患者全因死亡率的关联：系统评价和荟萃分析。
JAMA. 2018 Apr 17;319(15):1580-1591. doi: 10.1001/jama.2018.3024.
本文引用的文献
1
Effect of SGLT2 Inhibitors on Improving Glucolipid Metabolism and Reproductive Hormone Status in Overweight/Obese Women with PCOS: A Systematic Review and Meta-Analysis.SGLT2 抑制剂对改善超重/肥胖多囊卵巢综合征妇女糖脂代谢及生殖激素水平的影响：系统评价和荟萃分析。
Reprod Sci. 2024 May;31(5):1190-1203. doi: 10.1007/s43032-023-01415-5. Epub 2023 Dec 6.
2
Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies.胰高血糖素样肽-1类似物在多囊卵巢综合征治疗中有一席之地吗？新见解与前景广阔的疗法。
J Clin Med. 2023 Sep 12;12(18):5915. doi: 10.3390/jcm12185915.
3
Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease.胰高血糖素样肽-1受体激动剂及其他肠促胰岛素受体激动剂在非酒精性脂肪性肝病中的作用机制及可能的肝保护作用
Lancet Gastroenterol Hepatol. 2023 Feb;8(2):179-191. doi: 10.1016/S2468-1253(22)00338-7.
4
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.钠-葡萄糖共转运蛋白 2 抑制剂在非酒精性脂肪性肝病中的作用：超越糖尿病和心脏保护的角色。
Int J Mol Sci. 2022 Mar 13;23(6):3107. doi: 10.3390/ijms23063107.
5
Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂与胰高血糖素样肽-1（GLP-1）受体激动剂的联合治疗：对代谢及心肾风险的共生效应
Diabetes Ther. 2018 Jun;9(3):919-926. doi: 10.1007/s13300-018-0420-6. Epub 2018 Apr 5.
Zotero 插件